$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000144702821000021 Filed on March 04, 2021

Income Statement

Concept	2020 Q4	2020	2019 Q4
Revenue	$2.390M	$6.914M	$1.618M
YoY Change	47.71%	15.02%	-3.58%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.540M	$14.72M	$1.880M
YoY Change	88.3%	-16.98%	-68.3%
% of Gross Profit
Research & Development	$14.54M	$49.34M	$12.42M
YoY Change	17.07%	-14.35%	12.3%
% of Gross Profit
Depreciation & Amortization	$490.0K	$2.000M	$510.0K
YoY Change	-3.92%	-1.38%	2.0%
% of Gross Profit
Operating Expenses	$18.56M	$64.72M	$14.80M
YoY Change	25.41%	-56.83%	-15.43%
Operating Profit		-$57.81M	-$13.09M
YoY Change		-59.83%	-22.58%
Interest Expense	-$870.0K	$4.011M	-$11.57M
YoY Change	-92.48%	90.28%	386.13%
% of Operating Profit
Other Income/Expense, Net		-$5.939M
YoY Change		-73.58%
Pretax Income	-$17.04M	-$63.75M	-$24.65M
YoY Change	-30.87%	-61.69%	35.07%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$17.04M	-$63.75M	-$24.65M
YoY Change	-30.88%	-58.53%	35.1%
Net Earnings / Revenue	-712.97%	-921.97%	-1523.73%
Basic Earnings Per Share		-$1.00	-$0.46
Diluted Earnings Per Share	-$197.4K	-$1.00	-$418.0K
COMMON SHARES
Basic Shares Outstanding	84.91M shares	75.84M shares	56.85M shares
Diluted Shares Outstanding		75.84M shares

Balance Sheet

Concept	2020 Q4	2020	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$123.3M	$123.3M	$90.83M
YoY Change	35.71%	35.79%	-27.1%
Cash & Equivalents	$52.25M	$52.30M	$31.80M
Short-Term Investments	$71.02M	$71.00M	$59.04M
Other Short-Term Assets	$3.100M	$3.100M	$1.800M
YoY Change	72.22%	72.22%	-35.71%
Inventory
Prepaid Expenses
Receivables	$1.312M	$1.300M	$1.204M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$127.7M	$127.7M	$93.83M
YoY Change	36.1%	36.14%	-27.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.927M	$9.300M	$8.676M
YoY Change	-20.16%	-18.42%	-14.48%
Goodwill			$0.00
YoY Change			-100.0%
Intangibles			$0.00
YoY Change			-100.0%
Long-Term Investments	$0.00		$0.00
YoY Change			-100.0%
Other Assets	$44.00K	$0.00	$293.0K
YoY Change	-84.98%	-100.0%
Total Long-Term Assets	$9.376M	$9.400M	$11.71M
YoY Change	-19.91%	-19.66%	-88.14%
TOTAL ASSETS
Total Short-Term Assets	$127.7M	$127.7M	$93.83M
Total Long-Term Assets	$9.376M	$9.400M	$11.71M
Total Assets	$137.1M	$137.1M	$105.5M
YoY Change	29.89%	29.95%	-53.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.000M	$3.000M	$2.400M
YoY Change	25.0%	25.0%	-25.0%
Accrued Expenses	$6.300M	$6.300M	$5.200M
YoY Change	21.15%	21.15%	-31.58%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.541M	$9.500M	$7.828M
YoY Change	21.88%	21.79%	-30.35%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$25.60M	$25.60M	$25.00M
YoY Change	2.4%	2.4%	557.89%
Total Long-Term Liabilities	$25.60M	$25.60M	$25.00M
YoY Change	2.4%	2.4%	557.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.541M	$9.500M	$7.828M
Total Long-Term Liabilities	$25.60M	$25.60M	$25.00M
Total Liabilities	$35.11M	$35.10M	$32.79M
YoY Change	7.08%	7.01%	18.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.046B		-$970.1M
YoY Change	7.82%		20.48%
Common Stock	$985.9M		$898.5M
YoY Change	9.73%		2.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$102.0M	$102.0M	$72.74M
YoY Change
Total Liabilities & Shareholders Equity	$137.1M	$137.1M	$105.5M
YoY Change	29.89%	29.95%	-53.69%

Cashflow Statement

Concept	2020 Q4	2020	2019 Q4
OPERATING ACTIVITIES
Net Income	-$17.04M	-$63.75M	-$24.65M
YoY Change	-30.88%	-58.53%	35.1%
Depreciation, Depletion And Amortization	$490.0K	$2.000M	$510.0K
YoY Change	-3.92%	-1.38%	2.0%
Cash From Operating Activities	-$15.01M	-$51.44M	-$13.35M
YoY Change	12.43%	-27.55%	-21.84%
INVESTING ACTIVITIES
Capital Expenditures	-$150.0K	$229.0K	-$60.00K
YoY Change	150.0%	-61.12%	-73.91%
Acquisitions
YoY Change
Other Investing Activities	-$49.82M	-$14.68M	-$58.76M
YoY Change	-15.21%	-150.74%	-230.55%
Cash From Investing Activities	-$49.98M	-$14.91M	-$58.82M
YoY Change	-15.03%	-152.61%	-231.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$86.30M
YoY Change		363.94%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	20.21M	$86.75M	13.90M
YoY Change	45.4%	131.59%	12536.36%
NET CHANGE
Cash From Operating Activities	-15.01M	-$51.44M	-13.35M
Cash From Investing Activities	-49.98M	-$14.91M	-58.82M
Cash From Financing Activities	20.21M	$86.75M	13.90M
Net Change In Cash	-44.78M	$20.45M	-58.27M
YoY Change	-23.15%	-497.67%	-309.53%
FREE CASH FLOW
Cash From Operating Activities	-$15.01M	-$51.44M	-$13.35M
Capital Expenditures	-$150.0K	$229.0K	-$60.00K
Free Cash Flow	-$14.86M	-$51.67M	-$13.29M
YoY Change	11.81%	-27.83%	-21.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	City Area Code CityAreaCode	267
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-34949
CY2020	dei	Entity Registrant Name EntityRegistrantName	Arbutus Biopharma Corp
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0597776
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	701 Veterans Circle
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Warminster
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	18974
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Security12b Title Security12bTitle	Common shares, without par value
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Local Phone Number LocalPhoneNumber	469-0914
CY2020	dei	Trading Symbol TradingSymbol	ABUS
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	129686974	USD
CY2020Q2	us-gaap	Share Price SharePrice	1.82
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	95583915	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52251000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31799000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	71017000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	59035000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1312000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1204000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3124000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1790000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	127704000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	93828000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6927000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8676000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2405000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2738000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	44000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	293000	USD
CY2020Q4	us-gaap	Assets Assets	137080000	USD
CY2019Q4	us-gaap	Assets Assets	105535000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8901000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7235000	USD
CY2020Q4	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	250000	USD
CY2019Q4	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	253000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	390000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	340000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9541000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7828000	USD
CY2020Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	19554000	USD
CY2019Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	18992000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3426000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2953000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2593000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3018000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	35114000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	32791000	USD
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1164000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1164000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1164000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1164000	shares
CY2020Q4	us-gaap	Preferred Stock Including Additional Paid In Capital Net Of Discount PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount	149408000	USD
CY2019Q4	us-gaap	Preferred Stock Including Additional Paid In Capital Net Of Discount PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount	137285000	USD
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89678722	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	89678722	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	64780314	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	64780314	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	985939000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	898535000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60751000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	55246000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1045961000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-970093000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48171000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48229000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	101966000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	72744000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	137080000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	105535000	USD
CY2020	us-gaap	Revenues Revenues	6914000	USD
CY2019	us-gaap	Revenues Revenues	6011000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47481000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57601000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14724000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17727000	USD
CY2020	us-gaap	Depreciation Depreciation	1978000	USD
CY2019	us-gaap	Depreciation Depreciation	2028000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	473000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-173000	USD
CY2020	us-gaap	Restructuring Charges RestructuringCharges	64000	USD
CY2019	us-gaap	Restructuring Charges RestructuringCharges	156000	USD
CY2020	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2019	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	43836000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	22471000	USD
CY2020	us-gaap	Legal Fees LegalFees	0	USD
CY2019	us-gaap	Legal Fees LegalFees	6266000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	64720000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	149912000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-57806000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-143901000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	741000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	2111000	USD
CY2020	us-gaap	Interest Expense InterestExpense	4011000	USD
CY2019	us-gaap	Interest Expense InterestExpense	2108000	USD
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2545000	USD
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-22522000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-124000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	41000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5939000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-22478000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-63745000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-166379000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-12656000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-63745000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-153723000	USD
CY2020	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	12123000	USD
CY2019	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	11149000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-75868000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-164872000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.00
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.89
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	75835378	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	57093454	shares
CY2020	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	14000	USD
CY2019	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	0	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	-44000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToNoncontrollingInterest	59000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-63687000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-153782000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	200234000	USD
CY2019	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7204000	USD
CY2019	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	180000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	18601000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	307000	USD
CY2019	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax Period Increase Decrease TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease	-59000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-153723000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	72744000	USD
CY2020	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6145000	USD
CY2020	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	18000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	86297000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	449000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	14000	USD
CY2020	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax Period Increase Decrease TranslationAdjustmentFunctionalToReportingCurrencyNetOfTaxPeriodIncreaseDecrease	44000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-63745000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	101966000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-63745000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-153723000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-12661000	USD
CY2020	us-gaap	Depreciation Depreciation	1978000	USD
CY2019	us-gaap	Depreciation Depreciation	2028000	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-20000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	6161000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	6799000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	56000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	68000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	473000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-173000	USD
CY2020	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2019	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	43836000	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	22471000	USD
CY2019	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	1656000	USD
CY2020	abus	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	3957000	USD
CY2019	abus	Non Cash Interest Expense Related To Sale Of Future Royalties NonCashInterestExpenseRelatedToSaleOfFutureRoyalties	2099000	USD
CY2020	abus	Netequityinvestmentgainorloss Netequityinvestmentgainorloss	2545000	USD
CY2019	abus	Netequityinvestmentgainorloss Netequityinvestmentgainorloss	22522000	USD
CY2020	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	3395000	USD
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-210000	USD
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	275000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	108000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-227000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	752000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1606000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1666000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3314000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-375000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-744000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-51441000	USD
CY2019	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	87675000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-71006000	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	85578000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	58759000	USD
CY2020	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	73398000	USD
CY2020	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	2500000	USD
CY2019	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	11000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	229000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	589000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14909000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	28338000	USD
CY2020	abus	Proceeds From Sale Of Future Royalties Net ProceedsFromSaleOfFutureRoyaltiesNet	0	USD
CY2019	abus	Proceeds From Sale Of Future Royalties Net ProceedsFromSaleOfFutureRoyaltiesNet	18549000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	449000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	307000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	86297000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18601000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	86746000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	37457000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	56000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	20452000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5143000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31799000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36942000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52251000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31799000	USD
CY2020	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	12123000	USD
CY2019	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	11149000	USD
CY2020	us-gaap	Nature Of Operations NatureOfOperations	Organization<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Description of the Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Arbutus Biopharma Corporation (the “Company” or “Arbutus”) is a clinical-stage, biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (“HBV”) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that it believes have the potential to provide a new curative regimen for chronic HBV infection. The Company has also initiated a drug discovery and development effort for treating coronaviruses, including COVID-19. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company’s two lead product candidates are AB-729, the Company’s proprietary subcutaneously-delivered RNA interference (“RNAi”) product candidate that suppresses HBsAg expression, and AB-836, the Company’s proprietary next-generation oral capsid inhibitor that suppresses HBV DNA replication. AB-729 is currently in an ongoing Phase 1a/1b clinical trial and the Company expects AB-836 to progress into a Phase 1a/1b clinical trial in the first half of 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, the Company had an aggregate of $123.3 million in cash, cash equivalents and investments in marketable securities. From January 1, 2021 through March 3, 2021, the Company received an additional $24.3 million of net proceeds from the issuance of common shares under the ATM program. The Company believes that its cash resources will be sufficient to fund its operations through the third quarter of 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The Company’s research and development activities and commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company’s existing or future research and development programs or the Company’s ability to continue to fund these programs in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">COVID-19 Impact </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) was identified in Wuhan, China. This virus continues to spread globally, has been declared a pandemic by the World Health Organization and has spread to nearly every country in the world. The impact of this pandemic has been, and will likely continue to be, extensive in many aspects of society. The pandemic has resulted in and will likely continue to result in significant disruptions to businesses. A number of countries and other jurisdictions around the world have implemented extreme measures to try and slow the spread of the virus. These measures include the closing of businesses and requiring people to stay in their homes, the latter of which raises uncertainty regarding the ability to travel to hospitals in order to participate in clinical trials. Additional measures that have had, and will likely continue to have, a major impact on clinical development, at least in the near-term, include shortages and delays in the supply chain, and prohibitions in certain countries on enrolling subjects in new clinical trials. Future disruptions related to the COVID-19 pandemic could negatively impact the Company’s plans and timelines in 2021 and beyond, including enrolling and monitoring subjects in its clinical trials.</span></div>
CY2020Q4	abus	Number Of Products NumberOfProducts	2	product
CY2020Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	123300000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, revenue, expenses and contingent liabilities as of the end or during the reporting period. Actual results could significantly differ from those estimates. Significant estimates in the accompanying consolidated financial statements impact contingent consideration, income tax recoveries, stock-based compensation, clinical trial accruals and the sale of future royalties liability.</span></div>
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	31800000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28400000	shares
CY2020	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.0875
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject the Company to credit risk consist primarily of cash, cash equivalents and marketable securities. The Company holds these investments in highly rated financial institutions, and, by policy, limits the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</span></div>
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3400000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	500000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2953000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	473000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3426000	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3126000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	71003000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	15000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-173000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2953000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	71017000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	59035000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	59035000	USD
CY2019	abus	Netequityinvestmentgainorloss Netequityinvestmentgainorloss	22500000	USD
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2020Q4	abus	Lessee Operating Lease Numberof Leases LesseeOperatingLeaseNumberofLeases	2	lease
CY2020Q4	us-gaap	Lessor Operating Lease Renewal Term LessorOperatingLeaseRenewalTerm	P5Y
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000	USD
CY2020	abus	Fixed Lease Cost FixedLeaseCost	600000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	100000	USD
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000	USD
CY2019	abus	Fixed Lease Cost FixedLeaseCost	900000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	300000	USD
CY2019	us-gaap	Sublease Income SubleaseIncome	200000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y1M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.090
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	657000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	1116000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	677000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	581000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	598000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	616000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	635000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	787000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3894000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	911000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2983000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14548000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7621000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6927000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14318000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5642000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8676000	USD
CY2020Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	3566000	USD
CY2019	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	3400000	USD
CY2019Q4	abus	Disposal Group Including Discontinued Operation Property Plant And Equipment Net DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNet	100000	USD
CY2019	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-12700000	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	22500000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	0	USD
CY2020Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2994000	USD
CY2019Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2398000	USD
CY2019Q4	abus	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1433000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	679000	USD
CY2019Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	2314000	USD
CY2020Q4	abus	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1653000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	809000	USD
CY2020Q4	us-gaap	Restructuring Reserve RestructuringReserve	0	USD
CY2019Q4	us-gaap	Restructuring Reserve RestructuringReserve	137000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	144000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8901000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7235000	USD
CY2019Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	18992000	USD
CY2018Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	0	USD
CY2020	abus	Liability From Sale Of Future Royalties Non Cash Royalty Income LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome	3395000	USD
CY2019	abus	Liability From Sale Of Future Royalties Non Cash Royalty Income LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome	1656000	USD
CY2020	abus	Liability From Sale Of Future Royalties Non Cash Expense LiabilityFromSaleOfFutureRoyaltiesNonCashExpense	3957000	USD
CY2019	abus	Liability From Sale Of Future Royalties Non Cash Expense LiabilityFromSaleOfFutureRoyaltiesNonCashExpense	2099000	USD
CY2020Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	19554000	USD
CY2019Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	18992000	USD
	abus	Percent Of Costs Funded By Tpc PercentOfCostsFundedByTPC	0.27
	abus	Maximum Contribution For Product MaximumContributionForProduct	7200000	USD
	abus	Maximum Contribution For Product MaximumContributionForProduct	9300000	CAD
CY2020	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	2700000	USD
CY2020	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	3700000	CAD
CY2020	abus	Royalty Guarantees Commitments Percentage RoyaltyGuaranteesCommitmentsPercentage	0.025
CY2020Q4	abus	Alnylam Entitlements AlnylamEntitlements	2	product
CY2006Q2	abus	Number Of Chemotherapy Products With Worldwide Licenses NumberOfChemotherapyProductsWithWorldwideLicenses	3	chemotherapy_products
CY2020	us-gaap	Revenues Revenues	6914000	USD
CY2019	us-gaap	Revenues Revenues	6011000	USD
CY2020Q4	us-gaap	Employee Stock Ownership Plan Esop Shares In Esop EmployeeStockOwnershipPlanESOPSharesInESOP	1500000	shares
CY2020Q4	abus	Common Stock Discount On Shares Percentage CommonStockDiscountOnSharesPercentage	0.15
CY2020Q4	us-gaap	Employee Stock Ownership Plan Esop Shares In Esop EmployeeStockOwnershipPlanESOPSharesInESOP	1500000	shares
CY2020	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	200000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6161000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6799000	USD
CY2019	us-gaap	Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense	1100000	USD
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	7800000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-17211000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-44922000	USD
CY2019Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	16349000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	8356000	USD
CY2020	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	390000	USD
CY2019	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-525000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	622000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	3458000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	12033000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	19078000	USD
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	3716000	USD
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-3343000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	450000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	523000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	0	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	4719000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-12656000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3900000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1800000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3900000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	11700000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	11700000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-61900000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-61900000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-27100000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-139300000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	74351000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	59956000	USD
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	15812000	USD
CY2020Q4	abus	Deferred Tax Asset Book Amortization In Excess Of Tax DeferredTaxAssetBookAmortizationInExcessOfTax	737000	USD
CY2019Q4	abus	Deferred Tax Asset Book Amortization In Excess Of Tax DeferredTaxAssetBookAmortizationInExcessOfTax	914000	USD
CY2020Q4	abus	Deferred Tax Asset Revenue Recognized For Tax Purposes In Excess Of Revenue Recognized For Accounting Purposes DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes	5279000	USD
CY2019Q4	abus	Deferred Tax Asset Revenue Recognized For Tax Purposes In Excess Of Revenue Recognized For Accounting Purposes DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes	5128000	USD
CY2020Q4	abus	Deferred Tax Asset Tax Value In Excess Of Accounting Value In Lease Inducements DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements	627000	USD
CY2019Q4	abus	Deferred Tax Asset Tax Value In Excess Of Accounting Value In Lease Inducements DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements	705000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	3375000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	3038000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3897000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3897000	USD
CY2020Q4	abus	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Stock Options DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockOptions	2457000	USD
CY2019Q4	abus	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Stock Options DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockOptions	1632000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1218000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1111000	USD
CY2020Q4	abus	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	114795000	USD
CY2019Q4	abus	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	102762000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	114795000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	102762000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD

Files In Submission

Name	View Source	Status
0001447028-21-000021-index-headers.html	Edgar Link	pending
0001447028-21-000021-index.html	Edgar Link	pending
0001447028-21-000021.txt	Edgar Link	pending
0001447028-21-000021-xbrl.zip	Edgar Link	pending
abus-20201231.htm	Edgar Link	pending
abus-20201231.xsd	Edgar Link	pending
abus-20201231_cal.xml	Edgar Link	unprocessable
abus-20201231_def.xml	Edgar Link	unprocessable
abus-20201231_g1.jpg	Edgar Link	pending
abus-20201231_g2.jpg	Edgar Link	pending
abus-20201231_htm.xml	Edgar Link	completed
abus-20201231_lab.xml	Edgar Link	unprocessable
abus-20201231_pre.xml	Edgar Link	unprocessable
exhibit211_listingofsubsid.htm	Edgar Link	pending
exhibit231_eyconsent2020.htm	Edgar Link	pending
exhibit311_10-kcertceo2020.htm	Edgar Link	pending
exhibit312_10-kcertcfo2020.htm	Edgar Link	pending
exhibit321_soxcertceo2020.htm	Edgar Link	pending
exhibit322_soxcertcfo2020.htm	Edgar Link	pending
exhibit42descriptionofsecu.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2020 Q4 Form 10-K Financial Statement

#000144702821000021 Filed on March 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2020 Q4 Form 10-K Financial Statement

#000144702821000021 Filed on March 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus